Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of February 28, 2007, in conformity with Disclosure and Transparency Rules 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 6,009,165,189 Ordinary shares of 25p each.
- Treasury Shares: 257,482,678 Ordinary shares held in Treasury.
- Total Voting Rights: 5,751,682,511.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It presents a static snapshot of share capital and voting rights as of February 28, 2007.
Guidance, Outlook, and Risks
The filing text does not provide clear values or statements regarding guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,751,682,511) to determine if disclosure thresholds for shareholding interests have been met.
- Confirm the number of shares held in Treasury (257,482,678) when calculating the denominator for ownership percentage.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.